limaprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
prostaglandins 1581 74397-12-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • opalmon
  • limaprost alfadex
  • ONO1206
  • ONO 1206
  • limaprost
Limaprost exerts potent effects on vasodilation, increase of blood flow and inhibition of platelet aggregation, and thereby has proven clinical effects on various ischemic symptoms such as ulcer, pain and feeling of coldness associated with thromboangiitis obliterans.
  • Molecular weight: 380.53
  • Formula: C22H36O5
  • CLOGP: 3.44
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 3
  • TPSA: 94.83
  • ALOGS: -4.19
  • ROTB: 13

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
None PMDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiac failure 49.79 32.83 27 1176 89115 63398704
Interstitial lung disease 46.82 32.83 23 1180 61885 63425934
Osteonecrosis of jaw 45.49 32.83 19 1184 35104 63452715

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Interstitial lung disease 52.31 29.96 31 1199 65251 34890450
Decreased appetite 37.47 29.96 37 1193 166355 34789346
Cerebral infarction 29.97 29.96 16 1214 27439 34928262

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Interstitial lung disease 92.23 24.70 54 2710 112546 79629078
Cardiac failure 56.34 24.70 45 2719 154797 79586827
Hepatic function abnormal 41.92 24.70 28 2736 73079 79668545
Cerebral infarction 40.22 24.70 23 2741 45653 79695971
Decreased appetite 36.99 24.70 52 2712 342366 79399258
Osteonecrosis of jaw 36.01 24.70 21 2743 43205 79698419
Platelet count decreased 34.61 24.70 38 2726 194626 79546998
Inappropriate antidiuretic hormone secretion 30.79 24.70 16 2748 26297 79715327
Haemorrhage subcutaneous 27.08 24.70 9 2755 4800 79736824

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D002317 Cardiovascular Agents
MeSH PA D014665 Vasodilator Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Thromboangiitis obliterans indication 52403007 DOID:12918




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.42 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prostaglandin E2 receptor EP1 subtype GPCR AGONIST KEGG DRUG KEGG DRUG

External reference:

IDSource
D02722 KEGG_DRUG
C0064987 UMLSCUI
CHEMBL2107456 ChEMBL_ID
DB09211 DRUGBANK_ID
C059238 MESH_SUPPLEMENTAL_RECORD_UI
C525749 MESH_SUPPLEMENTAL_RECORD_UI
C025090 MESH_SUPPLEMENTAL_RECORD_UI
6438378 PUBCHEM_CID
5899 INN_ID
L02U804092 UNII

Pharmaceutical products:

None